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Chromosome alterations in breast carcinomas: frequent
involvement of DNA losses including chromosomes 4q
and 21q
A Schwendel1, F Richard1, H Langreck1, 0 Kaufmann1, H Lage1, KJ Winzer2, I Petersen1 and M Dietell
'Institute of Pathology, 2Department of Surgery, Charite, Humboldt University Berlin, Schumannstr. 20/21, D-10117 Berlin, Germany
Summary Comparative genomic hybridization was applied to map DNA gains and losses in 39 invasive ductal breast carcinomas. Frequent
abnormalities included gains on chromosomal regions lq, 8q, 11q12-13, 16p, 19, 20q and X as well asfrequent losses on 1p, 5q, 6q, 9p, llq,
13q and 16q. Furthermore, frequent losses on 4q (20 cases) and 21q (14 cases) were found for the first time in this tumour type. High copy
number amplifications were observed at 8q12-24, 11qll-13 and 20q13-ter. Highly differentiated tumours were associated with gains on 1q
and 11q12-13 along with losses on 1p21-22, 4q, 13q, 11q21-ter. Undifferentiated breast carcinomas were characterized by additional DNA
imbalances, i.e. deletions of 5q13-23, all of chromosome 9, the centromeric part of chromosome 13 including band 13q14 and the
overrepresentation of chromosome X. We speculate that these changes are associated with tumour progression of invasive ductal breast
cancer.
Keywords: breast cancer; comparative genomic hybridization; tumour genetics
The number of patients suffering from breast cancer, the most
common malignancy in women, is increasing worldwide.
Although, the vast majority ofcases appears to be sporadic, hered-
itary factors account for 5-10% ofall cases (Eeles et al, 1994) and
yet two predisposing genes, BRCAJ and BRCA2, have been identi-
fied (Futreal et al, 1994, Wooster et al, 1995)
Breast cancer is probably the most intensely studied tumour and
has been shown to be genetically heterogeneous (Sato et al, 1990).
This may at least partially explain why the molecular genetic alter-
ations underlying the disease progression are still not completely
understood. To our knowledge none ofthe studies evaluating chro-
mosomal imbalances and gene mutations have established a model
ofcritical events in sporadic breast cancer development.
The accumulation of genetic alterations in tumour-associated
genes are critically important and oncogenes such as erbB-2
(Tsuda et al, 1989; Clark et al, 1991), cyclin Dl (Hunter and Pines,
1994) and c-myc (Bland et al, 1995) have been shown to play a
role in breast cancer development. Similarly, the tumour-
suppressor genes p53 (Cunningham et al, 1994) and RB]
(Spandidos et al, 1992) are frequently inactivated. Importantly, the
activation ofoncogenes and the inactivation oftumour-suppressor
genes are frequently associated with DNA amplifications and
deletions respectively. Therefore, comparative genomic hybridiza-
tion (CGH) (Kallioniemi et al, 1992), allowing the complete
screening of a tumour genome for genetic imbalances, has estab-
lished itself as a powerful approach for pinpointing chromosomal
regions harbouring tumour-associated genes. Different CGH
studies on breast carcinomas (Isola et al, 1994, 1995; Kallioniemi
et al, 1994; Muleris et al, 1995; Ried et al, 1995; Courjal and
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Tirkkonen et al, 1997) described a complex pattern of gains and
losses of many chromosomes. The most common regions ofDNA
copy number increases were found on lq, 3q, 6p, 8q, 1lq, 12q, 17q
and 20q. DNA deletions were prevalent for 3p, 6q, 8p and 16q.
Analysing 39 invasive ductal breast carcinomas by CGH, we
detected frequent DNA underrepresentations on 4q and 21q forthe
first time in this tumour type. Poorly differentiated tumours were
found to exhibit more genetic changes than highly differentiated
carcinomas, suggesting that specific alterations are associated with
tumo.ur progression.
MATERIALS AND METHODS
Tumour specimens
The samples were collected from 39 patients with primary breast
cancer. Material was obtained from serial sections offrozen tissue
blocks used for intra-operative diagnosis. The tissue was stored at
- 80°C until DNA isolation. DNA was prepared by proteinase K
digestion and phenol-chloroform-isoamylalcohol extraction. The
proportion of tumour tissue exceeded 80% in each case.
Grading was performed according to the criteria defined by
Bloom and Richardson (1957). Nine breast carcinomas exhibited
high differentiation (GI). The majority (22 cases) were moderately
differentiated (G2) and the remaining eight tumours were poorly
differentiated (G3).
Comparative genomic hybridization
Hybridizations were performed as described previously
(Schwendel et al, 1997). The target metaphase slides were
prepared from phytohaemagglutinin-stimulated peripheral blood
lymphocytes from a healthy woman. Each batch of metaphases
was tested by hybridization of normal DNA as recommended by
Kallioniemi et al (1994).
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Figure 1 Summary of DNA copy number changes in 39 invasive ductal breast carcinomas. Vertical lines on the right side of each chromosome ideogram
represent a gain of genetic material in the tumour, whereas those on the left side correspond to a loss. Solid bars indicate a high copy number amplification
The normal DNA was labelled by nick translation with digoxi-
genin- 1I-dUTP (Boehringer Mannheim) and the tumour DNA
with biotin- I6-dUTP (Boehringer Mannheim). Aliquots of 1 peg of
each of the labelled DNAs together with 30 pg of human Cotl
DNA (Gibco) were hybridized to the normal metaphase chromo-
somes for 2-3 days at 37°C. The hybridizations were performed
sex neutrally, i.e. tumour DNA, normal DNA and metaphase
chromosomes were derived from female donors. Afterwards, the
tumour and normal DNA were detected by fluorescein avidin
(Vector Laboratories, Burlingame, CA, USA) and antidigoxi-
genin-rhodamine (Boehringer Mannheim, Germany) respectively.
Finally, the chromosomes were counterstained with 4,6-diamino-
2-phenylindole (Serva. Germany) for their identification.
Image acquisition and digital image analysis
Three fluorescence images per metaphase (DAPI, FITC/fluore-
scein, TRITC/rhodamine) were taken using an epifluorescence
microscope (Zeiss Axiophot, Oberkochen, Germany) and a cooled
CCD camera (Photometrics, Tucson, AZ. USA). Digital image
processing was facilitated by the software package KARYOTYPE
(IBSB, Berlin, Germany). The program is based on the digital
image analysis software AMBA, which was developed in our
laboratory (Roth et al, 1997).
The digital image analysis comprised the following steps: (a)
definition ofthe image objects (chromosomes) by segmentation of
the inverted DAPI image: (b) loading of the FITC and TRITC
images tinder the DAPI segmentation mask; (c) correction of the
optical shift of the FITC and TRITC image; (d) calculation of the
ratio (FITC/TRITC) image; (e) separation and karyotyping of the
chromosomes; (f) calculation of the mean ratio chromosomes
(CGH sum-karyogram) and the resulting mean ratio profiles by
averaging at least ten metaphases/karyograms; (g) definition of
sample subgroups and averaging their CGH sum-karyograms to
obtain the super-karyogram and the corresponding ratio profile
(Bockmuhl et al, 1996; Schwendel et al, 1997).
Ratio profiles were used to decide on the character of genetic
alterations. A deletion was defined by a fluorescence ratio less
than 0.75. Changes exhibiting a ratio greater than 1.25 were called
overrepresentations. If the fluorescence ratio exceeded 1.5, the
gain was a high copy number amplification.
Detailed information about the CGH preparation and
the digital image analysis are available on our Web site
http://amba.rz.charite.hu-berlin.de/cgh.
RESULTS
CGH was performed on 39 invasive ductal breast carcinomas. A
summary of all alterations is shown in Figure 1.
DNA losses
The most abundant DNA underrepresentations deduced from
Figure 1 are located on Ip (46%c of cases), 4q (5 1%). 1 Iq21-ter
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Overrepresentations were detected on chromosomes 19 (54%),
(49%) and 8q (49%). Additionally, gains on X, 1 1q12-13, 16p a
20q were observed in at least one-third of the cases. Seve
tumours showed high copy number amplifications of the chron
somal bands 8q12-24, 1lqI 1-13 and 20q13-ter.
Figure 2 Typical ratio profile for chromosome 21 from a single breast
tumour with a DNA loss of the band q21. If the mean ratio profile (red line) is
to the left of the fluorescence ratio 0.75 (left blue line) it was considered a
deletion. If the profile is on the right side of the 1.25 threshold (right blue line)
it was defined as a DNA gain. The green line corresponds to a FITC/TRITC
fluorescence ratio of 1.0 representing the equilibrium state with no DNA
imbalance of the tumour
(49%), 13q (82%) and 21q (36%). Further frequent deletions
occurring in more than 25% of cases were found in decreasing
order of frequency on 6q, 5q, 9p and 16q. Especially noteworthy
are the frequent losses on 4q and 21q, as they have not been found
before in breast carcinomas. The ratio profile ofchromosome 21 of
a single tumour averaged over ten metaphases is shown in Figure
2. It illustrates the frequent copy number loss, with the chromo-
somal band 21q21 being the smallest overlapping region in 14
cases. This chromosome was exclusively affected by deletions.
Chromosome 4
Gl
G3
Alterations vs histopathological grading
Our investigation shows that the average number ofalterations
tumour depends on the tumour grade. Highly differentiated ol
exhibit 8 ± 4 genetic changes, whereas the poorly differentia
tumours show 12 ± 5 alterations. Moreover, we found tumo
with different grading to have their own characteristic pattern
genetic changes. GC carcinomas were associated with DNA ga
on lq, llq12-13 as well as losses on lp21-22, 4q, 13q, IIq21-1
Similar alterations were found in poorly differentiated carcinom
In addition, the G3 tumours carried deletions at 5q13-23 and all
chromosome 9. For the majority of the low-grade tumours (
cases) the loss on chromosome 13q did not include region 13q
which was typical for the poorly differentiated carcinomas (
cases). Moreover, again ofthe entire chromosome X was obserN
in 75% (6/8 cases) of the poorly differentiated carcinomas.
illustrate these differences between highly and poorly differet
ated tumours, Figure 3 depicts the ideograms and CGH profiles
chromosomes 4, 5 and X which were derived from the respect
super-karyograms. In contrast to Figure 2, which represents
5 x
Figure 3 Alterations vs histopathological grading. The ratio profiles of chromosomes 4, 5 and X from the corresponding super-karyogram of all highly
differentiated (Gl) and from the super-karyogram of all poorly differentiated (G3) cases are shown as examples. Significant changes occur in poorly
differentiated cases at 4q as well as at 5q13-23 and X. Deletions are depicted in red, amplifications in green and normal DNA in blue. For definition of the linE
see Figure 2
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single tumour, these profiles were derived from nine and eight
cases, respectively.
DISCUSSION
This study presents a genome-wide survey ofDNA sequence copy
number changes in invasive ductal breast carcinomas using CGH.
The goal was to find new genetic alterations and to reveal patterns
of imbalances that are associated with tumour progression and
malignancy.
DNA amplifications
DNA amplification is an important mechanism of oncogene acti-
vation being associated primarily with tumour progression (Brison
et al, 1993). Amplifications were mapped to 1 lqll-13 and
8q12-24. These chromosomal regions include the loci of the
cvclin DI and c-myc proto-oncogenes. The first regulates the G S
transition whereas the second acts as a transcriptional modulator.
Both genes have been implicated in breast carcinogenesis (Bland
et al, 1995; Courjal et al, 1996). Additionally, we observed ampli-
fications on chromosome 20q. This aberration has been described
in previous studies (Ried et al, 1995; Solinas et al, 1996), being
characteristic of advanced carcinomas. The detailed analysis of
this region (Tanner et al, 1994) revealed a complex pattern of
amplicons showing adjacent non-overlapping amplimers.
Nevertherless, the CGH and fluorescence in situ hybridization
(FISH) studies have paved the way to the recent identification of
the candidate gene AIB1 (Anzick et al, 1997), which is amplified
in about 10% and overexpressed in 64% of primary breast carci-
nomas. Interestingly, it encodes a nuclear receptor co-activator
and interacts with the oestrogen receptor, which is intriguing as
a subgroup of breast cancer being in general of low-grade
malignancy is sensitive to treatment by anti-oestrogens.
DNA losses
Previous studies (Devilee et al, 1991; Eiriksdottir et al, 1995;
Kerangueven et al, 1995; Koreth et al, 1997) described losses of
heterozygosity (LOH) in breast cancer in a high percentage at lp,
6q, 9p, llq, 13q and 16q. In general, these allelic losses corre-
spond well to the most frequent DNA underrepresentations found
in our study.
Schmutzler et al (1996) found a correlation between the allelic
losses on llq and on 16q. This is consistent with our results as
70% of the cases with underrepresentations on 16 q also exhibited
DNA losses on 11q. The high rates of LOH observed within these
chromosomal regions suggest the involvement of tumour-
suppressor genes within these loci. A candidate gene for 16 q is E-
cadherini (16q22-24). It is involved in cell-cell adhesion and has
been reported to increase the invasive potential of tumour cells
(Rimm et al, 1995). However, the fact that the region 16q24-ter is
also affected in the LOH and CGH studies supports the notion that
multiple tumour-suppressor genes are located on this chromo-
somal arm (Tsuda et al, 1994). On 11q, the two regions
1 1q22-23.1 and 1 Iq25-ter in particular exhibit allelic losses in
sporadic breast cancer frequently (Koreth et al? 1997). The rele-
vance of these observations for the disease is emphasized by the
finding that patients whose primary tumours showed LOH on
II q23 exhibit a more aggressive post-metastatic disease course
than patients with primary tumours without these deletions
(Winquist et al, 1995). The ATM gene residing at 11q23 has been
implicated in tumour predisposition and sensitivity to radio-
therapy. The importance ofthis gene as a tumour suppressor is still
unknown. Again, there are probably multiple tumour-suppressor
genes on this chromosomal arm that may be involved in breast
cancer development (Laake et al, 1997).
DNA losses on 4q and 21q
This investigation revealed two novel frequent deletions in breast
cancer on 4q and 21q. Allelic loss on chromosome 4q has been
reported too in hepatocellular, respiratory tract cancer, malignant
mesothelioma and also familial breast cancer (Bockmuhl et al,
1996; Bjorkqvist et al, 1997; Marchio et al, 1997; Petersen et al,
1997a, b; Tirkkonen et al, 1997). Our collective was not investi-
gated for hereditary predisposition. However, the high rate of
DNA deletions on 4q suggests that as yet unidentified tumour-
suppressor gene(s) are involved in multiple tumour types
including sporadic breast cancer.
DNA underrepresentations were also frequently observed at
21 q. LOH on chromosome 21q has been reported in epithelial
ovarian carcinomas (Cliby et al, 1993), adenocarcinomas of the
stomach (Tamura et al, 1996) and renal tumours (Polascik et al,
1996), but not in breast carcinomas. Our CGH study indicates the
chromosomal band 21q21 as the smallest overlapping region
harbouring putative tumour-suppressor genes. A recent LOH study
in adenocarcinomas of the stomach revealed two separate
commonly deleted regions, suggesting that also for this chromo-
some at least two genes might be involved in tumorigenesis
(Sakata et al, 1997).
DNA losses vs histopathological grading
Our study presented evidence that tumours of the same grade are
characterized by a recurrent pattern of genetic aberrations. In
general, changes occurring in highly differentiated tumours were
also found in poorly differentiated carcinomas. However, the high-
grade tumours showed additional gains and losses.
In breast carcinomas, DNA deletions on 5q have been described
particularly by Tirkkonen et al (1997). They showed that the
genetic change on 5q must be preceded by other alterations.
Accordingly, we identified DNA deletions on 5q13-23 predomi-
nantly in poorly differentiated invasive ductal breast carcinomas.
Various candidate genes such as ZNF5 (Wasmuth et al, 1989),
MCC (Kinzler et al, 1991) orAPC (Groden et al, 1991) have been
isolated. However their role in breast carcinogenesis is still largely
unknown.
DNA losses on 13q have been reported in a variety of tumours.
Our study suggests that the centromeric region including the band
13q14 was lost, particularly in the poorly differentiated tumours,
whereas the highly differentiated carcinomas revealed deletions of
the distal part. This observation is paralleled by our findings in
small-cell lung carcinomas (SCLCs) and non-small cell lung
cancer (NSCLC). SCLC, being the most malignant and highly
metastatic lung tumour, showed deletions on 13q including the RB
locus at 13ql4, which was generally spared by NSCLC (Petersen
et al, 1997a, 1997b). The association of deletions and RBI inacti-
vation in lung cancer is well established (Kelley et al, 1995).
However, the situation in breast cancer seems to be more compli-
cated (Borg et al, 1992) and the association with parameters of
tumour progression is still controversial (Andersen et al, 1992;
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Spandidos et al, 1992). In summary, our study indicates multiple
regions ofDNA deletions that are affected in breast carcinomas. It
supports the notion that the type and localization ofthe aberrations
is as important for the malignant phenotype as the bare number of
changes. The analysis of additional tumours and the evaluation of
tumour groups by statistical means will help to refine the chromo-
somal localization ofcancer-associated genes.
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